Novartis CFO: improved outlook for Sandoz has no impact on strategic review

FRANKFURT (Reuters) - An improved earnings outlook for Sandoz, the generic-drug unit of Swiss pharmaceuticals giant Novartis, has no impact on the ongoing strategic review of the business, Novartis' finance chief said on Tuesday.

"I strongly believe one needs to follow the best-owner principle," Chief Financial Officer Harry Kirsch told journalists in a call following the release of second-quarter results.

(Reporting by Ludwig Burger)